In the phase I/II trial of daraxonrasib, tumours stopped growing in 90% of patients. Just over 60% of patients saw their tumours shrink or disappear. For around 8% of patients, described as one in 12, tumours became undetectable on CT scans. The trial involved 61 patients who had recently been diagnosed with advanced pancreatic cancer that had spread to other parts of the body. Tumours stopped growing in almost all of those participants.
How the drug works
Daraxonrasib is a targeted inhibitor treatment that has already been approved in the US. It is a KRAS inhibitor that locks on to and shuts off RAS mutations, which are found in most pancreatic cancers and drive tumour growth. Dozens of other cancers, including lung and ovarian cancers, can have similar RAS mutations, so the drug might help other patients too.
Follow-up and caution
The trial followed patients for a year and a half on average, and some patients did not see their cancer return during this time. Doctors stress that it is unclear how long daraxonrasib might keep the disease at bay, and that it should not be seen as a cure. Cancer can come back even when scans show no sign of it, so people do not necessarily know they are cancer-free until more time has passed. Longer studies are needed to understand whether any of these cancers can be put into remission and for how long.
Reaction from doctors
Dr Wungki Park of Memorial Sloan Kettering Cancer Center, who is involved in the trial, said the results were extremely encouraging so far. He cited a higher percentage of tumour response rates, deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival. Prof Elena Garralda said the combined treatment could potentially significantly improve overall survival, as well as the time before tumours start to grow again. Cancer Research UK described the results as the biggest leap forward in decades for pancreatic cancer patients. Dr Sam Godfrey of the charity called the results incredibly exciting and described the drug as finding a way of drugging the undruggable.
Background on pancreatic cancer
Chemotherapy can shrink pancreatic tumours a bit, but the cancer often grows again. Most patients with advanced disease survive months, not years. Pancreatic cancer accounts for about 3% of all cancers in the United States and about 8% of all cancer deaths, killing around 53,000 people a year. In the UK it has the lowest survival rate of all common cancers and is notoriously hard to treat. In Britain, there are 11,500 diagnoses each year and around 10,200 deaths, according to Cancer Research UK.
The results are being presented to other doctors at the EORTC–NCI–AACR Symposium 2026, a European cancer conference chaired by Prof Elena Garralda.